NEW YORK: US pharmaceutical giant Johnson & Johnson must pay $8 billion as compensation as they failed to warn that their psychiatric drug could cause breast growth in men, within the label, ruled out a Pennsylvania jury on Tuesday.
A customer named Nicholas Murray at Philadelphia court blamed that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, bought from Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, caused breast growth on him.
However, the company challenged the verdict and called the compensation as ‘grossly disproportionate’ as they have already given $680,000 as of the initial award to the plaintiff.
According to a statement released by the firm, they are very confident that the verdict will be overturned and will be immediately moved to set aside this excessive and unfounded verdict.
In the statement, Johnson and Johnson also accused that the court did not allow their lawyers to present the Risperdal labelling as ‘key evidence’ against the plaintiff’s accusations.
Recently, the company has named in a series of many cases filed in Pennsylvania, California, and Missouri for not properly mentioning the cautions in their product label especially in the Risperdal regarding its side effects.
The drug Risperdal which is made for the treatment of adults was approved by the US Food and Drug Administration in 1993.